Index

ABANDONMENT	APPLICATION FOR A PATENT
Generally, 9:72 to 9:77	—Cont'd
Circumstances, 9:72	Applications filed before October 1, 1989
Good faith reply, 9:73	— "Old Act applications"—Cont'd
Timely completion of application, 9:74	priority date, 9:94 —Cont'd
Timely payment of fees, 9:77	same invention, 9:94
Timely payment of maintenance feeds,	significance of, 9:94
9:75	public inspection, not open to, 9:95 to
Timely request for examination, 9:76	9:100
ACCOUNT OF PROFITS	substances intended for food, 9:101
Generally, 14:47 to 14:59	Applications filed on or after October 1,
Apportionment, 14:56	abandonment, 9:72 to 9:77
Condonation, 14:59	circumstances, 9:72
Expenses, 14:55	good faith reply, 9:73
Indirect profits, 14:57	timely completion of application,
Interest, 14:58	9:74
Measure of profits, 14:49	timely payment of fees, 9:77
differential cost approach, 14:51	timely payment of maintenance fees
differential profits approach, 14:52	9:75
full cost approach, 14:50	timely request for examination, 9:76
Multiple parties, 14:48	allowance of an application, 9:83
Proof of the expenses, 14:54	amendments, 9:61 to 9:65
ACENT	after allowance, 9:65
AGENT	application, 9:61
See PATENT AGENT	include sequence listings, 9:63
APPLICATION FOR A PATENT	limitation after rejection, 9:64
Generally, 9:1 et seq.	new matter, 9:62
Additional term, 9:85.20 to 9:85.40	appeal from decision of commissions,
Applications filed before October 1, 1989	9:86 to 9:90
— "Old Act applications"	appeal decisions, 9:90
amendments, 9:103	appeal to federal court, 9:86
supplementary disclosure, 9:103	powers of the federal court, 9:89
conflicting applications, 9:104 to 9:106	procedure on appeals, 9:87
conflict exists, 9:104	standard of review, 9:88
federal court, 9:106	appeal to the patent appeal board, 9:82 application, 9:31 to 9:36
patent office, 9:105	abstract, 9:33
due care, 9:78.50	petition, 9:32
examination, 9:102	specification, 9:34
priority date, 9:94	appointment of patent agents, 9:22
convention priority, 9:94	appointment of patent agents, 9:22 appointment of representative, 9:23
earliest corresponding foreign	claim date, 9:38 to 9:45
application, 9:94	applicant, request for priority by,
foreign application, 9:94	9:44
· 11	

PPLICATION FOR A PATENT	APPLICATION FOR A PATENT
—Cont'd	—Cont'd
Applications filed on or after October 1, 1989—Cont'd	Applications filed on or after October 1, 1989—Cont'd
claim date, 9:38 to 9:45—Cont'd	joint inventors and applications, 9:12 to
disclosure of subject matter, 9:42	9:21 —Cont'd
filing date, 9:43	power of commissioner, 9:16, 9:17
multiple priorities, effect of, 9:45	section 31 appeal, 9:18
prior application, 9:41	judicial review, 9:91
prior Canadian application, 9:39	misrepresentation, 9:79
prior convention or Treaty applica-	postal services interruption relief, 9:92
tion, 9:40	publication of the application, 9:53
requirements, 9:38	confidentiality period, 9:54
completing the application, 9:52	secret applications and patents, 9:56
conflicting applications, 9:81	significance of the publication date,
corrections, 9:66	9:55
divisional applications, 9:68	
examination, 9:57 to 9:60	refusal to grant patents, 9:85 reinstatement, 9:78
accelerated examination, 9:58	
prosecution of application, 9:59	requesting priority, 9:46 to 9:51
request for examination, 9:57	withdrawal of request, 9:47
timely response in good faith, 9:60	third party filing, 9:80
fees, 9:25 to 9:30	time, 9:24
current status, 9:28	Commission of patents, 9:2 to 9:4
fees for "small entity" applicants,	Patent agents, 9:5
9:26 to 9:28	new patent agent privilege, 9:5
legislative correction, 9:27	solicitor-client privilege, 9:5
maintenance fees, 9:29	Patent office, 9:2 to 9:4
reduced fees, 9:26	communications with the patent office,
filing date, 9:37	9:4
filing prior art, third party, 9:80	manual of patent office practice
good faith, issues of, 9:69 to 9:71	(MOPOP), 9:3
granting patent, 9:67	DIOTECHNOLOGY
grant of a patent, 9:84	BIOTECHNOLOGY
inventor, application by, 9:9	Generally, 3:40 to 3:45
inventor's legal representative, applica-	Animals, 3:44
tion by, 9:9	Higher life forms, 3:42
joint inventors and applications, 9:12 to	Inventions
9:21	biochemical, 3:40
appeal from decision of commission,	biological, 3:40
9:18	Lower life forms, 3:41
changing inventors named in patent,	Plants, 3:45
9:21	CLAIM DATE
consequences of misnaming inven-	
tors, 9:20	Generally, 9:38 to 9:45
effect of refusal, 9:13	Applicant, request for priority by, 9:44
joining persons, 9:15	Disclosure of subject matter, 9:42
joint applicant had no part in inven-	Filing date, 9:43
tion, 9:14	Multiple priorities, effect of, 9:45
joint investors, ownership rights of,	Prior application, 9:41
0.10	Prior Canadian application 0.30

CLAIM DATE—Cont'd	CONSTRUCTION OF THE PATENT
Prior convention or Treaty application,	—Cont'd
9:40	Rules of construction, 8:11 to 8:37
Requirements, 9:38	claims language, 8:31 to 8:35
COLLEGE OF PATENT AGENTS AND	consideration of variants, 8:32
TRADEMARK AGENTS	determination of essential elements, 8:34
Generally, 16:1 et seq.	essential elements, 8:33
COMMON GENERAL KNOWLEDGE	purposive construction, 8:31
IN THE ART	U.K. law, 8:35
Construction of a patent	consider whole claim, 8:28
consideration of the common general	construed as a whole, 8:20
knowledge of a person skilled in	plain and ambiguous language, 8:20
the art, 8:15	construed objectively, 8:21
Obviousness	construed to avoid unreasonable result
determination of obviousness, 4:46 to	8:27
4:56	context, 8:26
relevance of the common general knowledge in the art, 4:37	date of publication, 8:12
The specification	disclaimed, 8:37
common general knowledge in the art	extrinsic evidence, 8:22
re the specification, 7:6	factual matrix, 8:19
What is the common general knowledge	meaning of term, 8:19 interpretation, consistency in, 8:30
in the art, 4:38	interpretation, consistency in, 8:30
,	language, interpretation of, 8:29
CONSTRUCTION OF THE PATENT	language of patent specification, 8:26
Generally, 8:1 et seq.	person of ordinary skill in the art, 8:13
Claims, types of, 8:48 to 8:52	to 8:18
"Jepson" claims, 8:51	application, 8:17
"Markush" claims, 8:52	common general knowledge, 8:15
product by process claims, 8:49	expert evidence, 8:16
product claims, 8:48	person skilled in art, 8:14
"Swiss Form" claims, 8:50	separate claims, 8:14
"for," 8:50	purposive construction, 8:24
Consideration, 8:64	read fairly, 8:25
Experts, role of, 8:63	redraft, should not, 8:36
First duty of court, 8:1	Specification, construction of, 8:38 to
interpretation, 8:1	8:47
General principles, 8:7 to 8:10	Specification, issues concerning, 8:38 to
abstract, 8:9	8:47
approach, 8:7	alternatives, 8:41
description, role of, 8:8	dependence claims, 8:43, 8:44
drawings, role of, 8:8	antecedent claims, 8:43
function of the claims, 8:10	element, included or additional, 8:4 4
Historical developments, 8:4 to 8:6	inventions, single or multiple, 8:40
Canadian rules, 8:6	new result or method, 8:39
rules prior to 1981, 8:4	new technology, 8:47
U.K. rules, 8:5	numerical limitations, 8:46
Issue of law, 8:2	promise of patent — old law, 8:38
Prior decision, 8:65	reference numbers, 8:42

CONSTRUCTION OF THE PATENT	DEDICATION TO THE PUBLIC
—Cont'd	Generally, 12:40 to 12:42
Specification, issues concerning, 8:38 to	Dedication, 12:40
8:47 —Cont'd	Effect of dedication, 12:42
reference to another claim, 8:45	Reasons for dedication, 12:41
Terms, 8:53 to 8:62	DESCRIPTION OF INVENTION
"about," 8:53	Generally, 7:9 to 7:25
"approximately," 8:54	Clarity, 7:18
"comprising," 8:55	ambiguity, 7:19
"contain," 8:56	definition of materials, 7:21
"for," 8:57	errors and inaccuracies, 7:20
functional claims, 8:58	proportions of ingredients, 7:22
"obvious chemical equivalent," 8:59	Failure to meet disclosure requirements,
pharmaceutical preparation, 8:60	7:25
relative terms, 8:62	Good faith, 7:23
"treatment," 8:61	Misleading matter, 7:24
Types of claims, 8:48 to 8:52	Nature of the invention, 7:10
"Jepson" claims, 8:51	Necessity for experiments, 7:16
"Markush" claims, 8:52	Operation and use, 7:11
product by process claims, 8:49	Reference to previous documents, 7:17
product claims, 8:48	Standards for disclosure, 7:12 to 7:15
"Swiss Form" claims, 8:50	contemplated by the inventor, 7:13
Written instruments, 8:3	general points, 7:12
Interpretation Act, 8:3	DISCLAIMER
CORRECTION	Generally, 12:18 to 12:27
Certificate of correction for clerical errors,	British authorities, 12:23
12:28 to 12:30	Effect, 12:27
Correction by the court, 12:31	Extent, 12:24
·	Form, 12:26
DAMAGES	Function, 12:25
Generally, 14:17 to 14:45	History
Absence of licences, 14:27	Canada, 12:20
Aggravated damages, 14:45	U.K., 12:18
Alternatives, 14:43	U.S., 12:19
Damages from use, 14:28	Statutory provisions for disclaimer, 12:21
Effect of licences, 14:26	United States authorities, 12:22
Loss due to price reduction, 14:37 to 14:39	DICCLOSUDE
	DISCLOSURE
market disruption, 14:38	Generally, 5:1 et seq.
post infringement losses, 14:39	Applicant, 5:50
Loss of profit, 14:29 to 14:36 Lost sales, 14:29 to 14:36	Filing date, 5:49 to 5:52
	General considerations, 5:15
Measure of damages, 14:18	Infringe, 5:17
Mitigation, 14:42	Patent or publication, disclosure by, 5:32 to 5:48
Plaintiff's loss, 14:19	
Profits of infringer, 14:19	claimed subject matter, 5:43
Reasonable royalty, 14:41	construction, 5:36
Recovery of plaintiff's damages, 14:44	directions, 5:43
Sales patentee, 14:40	drawing, 5:37

DISCLOSURE—Cont'd	EXPERT EVIDENCE—Cont'd
Patent or publication, disclosure by, 5:32	Expert evidence to assist construction of
to 5:48 —Cont'd	the patent, 8:2, 8:16, 8:26
enabling disclosure, 5:44	Proof of infringement, 13:14
evidence of obviousness, 5:48	FILING APPLICATIONS, OLD ACT
exact prior description, 5:42	Generally, 9:93
experiments, 5:41	Benefit, 9:94
language, 5:35	Conflicting applications, 9:104 to 9:106
no mosaic of documents, 5:34	conflict exists, 9:104
oral disclosure, 5:38	federal court, 9:106
paper anticipation, 5:47	patent office, 9:105
photograph, 5:37	Convention priority, 9:94
prior description, 5:32	Earliest corresponding foreign applica-
public accessibility, 5:33	tion, 9:94
same invention, 5:39	Examination, 9:102
similarity of language, 5:45	Foreign application, 9:94
sufficiency of description, 5:40	No new matter, 9:103
use unnecessary, 5:46	Priority date, 9:94
Person skilled in the art, 5:18	significance of, 9:94
Public, 5:12 to 5:14	Public inspection, not open to, 9:95 to
art cited in the patent, 5:13	9:100
available to the public, 5:12	Same invention, 9:94
enabling disclosure, 5:14	Substances intended for food, 9:101
Public use or sale, 5:22 to 5:31	Supplementary disclosure, 9:103
accidental use, 5:31	INFRINGEMENT
analogous use, 5:25	Generally, 13:1 et seq.
enabling disclosure, 5:26 experimental use, 5:29	Assignee, 13:69
impractical device, 5:27	Burden of proof, 13:8
inoperable device, 5:27	Canada, must occur in, 13:47
method or result, 5:30	Cause of action, 13:72
same invention, 5:24	Constructing, 13:38 to 13:46
secret use, 5:28	Construction of patent, 13:10
Same invention, 5:16	Construed infringement, 13:11 to 13:16
Without experimentation, 5:19	approach, 13:11
Without invention, 5:19	combinations, 13:13
	common law, 13:16
DOUBLE PATENTING	intention, 13:12
Generally, 11:13 to 11:18	new product, 13:15
EXAMINATION	presumption, 13:15
Generally, 9:57 to 9:60	proof of infringement, 13:14
Accelerated examination, 9:58	Crown right to use, 13:66
Prosecution of application, 9:59	Exclusive right of patentee, 13:6 to 13:8
Request for examination, 9:57	Expiry, effect of, 13:35
Timely response in good faith, 9:60	"Gillette defence," 13:17
EXPERT EVIDENCE	Historical, 13:2 , 13:3
Expert evidence as to the prior art, 4:32	Inducing infringement, 13:49
Expert evidence as to the prior art, 4:32 Expert evidence as to the qualities and	affiliated companies, 13:52
capabilities of the person skilled in	aiding and abetting, 13:54
the art. 4:35	common design, 13:53

INFRINGEMENT—Cont'd	INTERNATIONAL PATENT
Inducing infringement, 13:49—Cont'd	PROTECTION—Cont'd
good faith belief in invalidity, 13:49	Paris convention, 10:2
supplying product, 13:50	Patent Cooperation Treaty (PCT), 10:3
vicarious liability, 13:55	amendment of the claims, 10:7
Infringement by directors and by officers	examination, 10:9
and other employees, 13:56	international application, 10:4
Infringing Acts, 13:19	international publication, 10:8
Liability for patent infringement, 13:67	international search, 10:5
Liability, partners, 13:55.50	national phase entry, 10:12, 10:13
Liability, partnerships, 13:55.50	right to practice, 10:10
Licensee, 13:70	third party observations, 10:6
Making, 13:38 to 13:46	time limits, 10:11
Non-infringement defences, 13:57 to	Patent Law Treaty (PLT), 10:18
13:65	Strasbourg Agreement, 10:19
experimental and developmental, 13:57	Trade-Related aspects of Intellectual
foreign vehicle entering Canada	Property Rights (TRIPS), 10:15
temporarily, 13:61	TRIPS and patents, 10:16
laches and acquiescence, 13:63	TRIPS disputes, 10:17
licence, 13:59	World Intellectual Property Organization
limitation period, 13:62	(WIPO) Treaty, 10:21
manufacture, 13:58	•
patent misuse, 13:64	INVENTION
use and sale, 13:60	Generally, 2:1 et seq.
Old Act patents, 13:4 , 13:5	Accidental discovery, 2:8
Patentee, 13:68	Date of invention, 2:10
Patentee, persons claiming under, 13:71	Definition in Patent Act, 2:3
Patent term, activity during, 13:20 to	Discovery, 2:7
13:37	Idea, 2:6
articles acquired prior to filing, 13:21	Inventive ingenuity, 2:4
to 13:28	Inventor: CITE2:11
correction, 13:32	historical background, 2:12
dedication, 13:34	Patent Act, 2:13
disclaimer, 13:31	Making an invention, 2:9
re-examination, 13:33	Patent granted, 2:1
reissue, 13:30	JOINT INVENTORS AND
Purposive construction, 13:2	APPLICATIONS
Selling, 13:38 to 13:46, 13:48	Generally, 9:12 to 9:21
Statutory grant, 13:18	Appeal from decision of commission,
Three aspects of patent infringement, 13:7	9:18
U.K. law, 13:3	Appeal under section 31, 9:18
Using, 13:38 to 13:46, 13:48	Changing inventors named in patent, 9:21
	Consequences of misnaming inventors,
INTERNATIONAL PATENT PROTECTION	9:20
Generally, 10:1 et seq.	Effect of refusal, 9:13
Canada-European Union, Comprehensive	Joining persons, 9:15
Economic and Trade Agreement	Joint applicant had no part in invention,
(CETA), 10:20	9:14
North America Free Trade Agreement	Joint investors, ownership rights of, 9:19
(NAFTA), 10:14	Power of commissioner, 9:16, 9:17

LICENSEE	NOVELTY—Cont'd
Right of action for patent infringement, 13:70	Patent or publication, 5:32 to 5:48 —Cont'd
MAINTENANCE FEES	enabling disclosure, 5:44
Generally, 9:29, 11:20	evidence of obviousness, 5:48
•	exact prior description, 5:42
NOVELTY	experiments, 5:41
Generally, 5:1 et seq.	language, 5:35
Anticipation of novelty, 5:2	no mosaic of documents, 5:34
Common general knowledge, 5:11	oral disclosure, 5:38
Consideration of novelty, 5:54 to 5:65	paper anticipation, 5:47
chemical product, 5:56	person skilled in the art, 5:18
claims made by a particular process,	photograph, 5:37
5:57	prior description, 5:32
combinations, 5:54	public accessibility, 5:33
confidential communications, 5:64	same invention, 5:39
enantiomers, 5:60	similarity of language, 5:45
new use, 5:58	sufficiency of description, 5:40
novelty in part, 5:62	use unnecessary, 5:46
process, 5:55	Person skilled in the art, 5:10
product for a new use, 5:59 rediscovery, 5:63	Prior foreign grant, section 27(2), 5:79
selection patents, 5:61	Prior to invention, knowledge or use, Old Act, 5:68 to 5:74
Co-pending patent applications, section	conflict, 5:73
28.2(1)(c),(d), 5:53	disclosure to public before filing date,
Description in patent or publication, 5:75	5:72
anticipation under sections 27(1)(b) and	invention date, 5:69
28(2), 5:77	section 61, 5:71
printed publication, 5:76	section 61(3), 5:74
Development of requirements, 5:3 , 5:4	Public, 5:12 to 5:14
Canadian laws, 5:4	art cited in the patent, 5:13
U.K. laws, 5:3	available to the public, 5:12
Disclosure	enabling disclosure, 5:14
anticipate, 5:17	Public use or sale, 5:22 to 5:31
filing date, 5:49 to 5:52	accidental use, 5:31
applicant, 5:50	analogous use, 5:25
one year before filing date, 5:51	before filing date, 5:78
general considerations, 5:15	enabling disclosure, 5:26
infringe, 5:17	experimental use, 5:29
Enablement, 5:21	impractical device, 5:27
Essential nature, 5:1	inoperable device, 5:27
Evidence of novelty, 5:66	method or result, 5:30
Lack of novelty, 5:2	same invention, 5:16 , 5:24
Novelty applications, 5:80	every essential element claimed,
Old Act, 5:67	5:24
Patent or publication, 5:32 to 5:48	secret use, 5:28
claimed subject matter, 5:43	without experimentation, 5:19
construction, 5:36	without invention, 5:20
directions, 5:43	Relevant dates, 5:9
drawing, 5:37	Requirement of novelty, 5:1

NOVELTY—Cont'd	OBVIOUSNESS—Cont'd
Statutory requirements, current Act, 5:6	Meritorious awards, 4:67
Subject matter defined by claim, 5:8	Motive to find the solution, 4:58
Test for anticipation, 5:5	New use for old product or process, 4:77
Beloit test, 5:5	Non-obviousness requirement, 4:3 to 4:6
OBVIOUSNESS	Canadian law, 4:6
Generally, 4:1 et seq.	U.K. law, 4:4
Age of the prior art, 4:27	U.S. law, 4:5
Anticipation, 4:2	Omission, 4:80
Application of test for, 4:72 to 4:84	Overview, 4:1
Cited art, 4:23	Patent Act, section 28.3, 4:9
Claim, 4:39 to 4:45	Patents, 4:68
Climate in the art, 4:63	Post-art, 4:25
Combination of factors, 4:69	Prior art
Combinations, 4:72	expert evidence as to, 4:32
Commercial success, 4:65	Old Act, 4:16
Common general knowledge in art, 4:37 ,	Patent Act, 4:17 to 4:20
4:38	Priority date, 4:14
relevance, 4:37	Product for a new use, 4:78
Composition, 4:82	Proof of actual date of invention, 4:13
Constructive date of invention, 4:14	Proportions, 4:81
Current Act	Prosecution of patent application, 4:24
information disclosed, 4:18, 4:19	Question of fact, 4:52
Date of invention, 4:12 to 4:14	Recently disclosed technology, 4:75
filing date, 4:14	Reception of invention, 4:66
Determination of, 4:46 to 4:56	Relevance of a diligent search, 4:29
directly and without difficulty, 4:50	Relevant art, 4:22
relevant date, 4:54	Relevant date for obviousness
Disclosure, 4:21	Old Act, 4:12 to 4:14
Effort required to achieve invention, 4:60	Patent Act section 28.3, 4:15
Expert evidence, prior art, 4:32	Selection, 4:79
Factors for determining, 4:57 to 4:69	broad class, 4:73
activities of others, 4:66	Shape, 4:81
File record, relevance of, 4:70	Simplicity, 4:61
File wrapper, relevance of, 4:70	utility, 4:62 Size, 4:81
Hindsight, caution concerning, 4:55	Skilled in the art, person, 4:33 to 4:36
Idea, 4:80	identify the person, 4:33 to 4.30
Industry praise, 4:67	notional person, 4:34
Information outside the field, 4:26	qualities and capabilities, 4:35
Invention, 4:48	expert evidence as to, 4:36
inventive ingenuity, 4:48	admissibility of expert evidence,
Inventive concept, 4:39 to 4:44	4:36
general principles, 4:42	other, 4:35
U.K. law, 4:40	State of the art, 4:45
Issues to consider, 4:21 to 4:31	Statutory test for obviousness, 4:9, 4:10
Locating art, 4:30	Subject-matter defined by the claim, 4:11
Manner of making the invention, 4:59	Test for obviousness
Material, 4:81	Current Act, 4:9, 4:10
Mechanical skill, 4:53	Old Act, 4:7, 4:8
Tricenamear Skin, T.JJ	Jiu 1101, T.1, T.0

OBVIOUSNESS—Cont'd	PATENTS—Cont'd
Tests concerning prior art, 4:31	Obtaining by application, 1:4
repitition, 4:31	Patent Act, 1:5, 1:13 to 1:28
PATENT AGENT	history, 1:29 to 1:53
College of Patent and Trademark Agents,	since 1989, 1:29 to 1:42
16:1 et seq.	transition provisions, 1:43 to 1:53
Patent Agents, 9:5	which Patent Act applies, 1:43 to 1:53
Appointment of Patent Agents, 9:23	Patented Medicines (Notice of Compli-
Patent Agent Privilege, 9:8	ance) Regulations, 1:56
Representation by a Patent Agent, 9:6	Patented Medicines Process Review
Retainer of a Patent Agent, 9:7	Board, 1:57
· ·	Patented Medicines Regulation, 1:55
PATENT GRANT AND VALIDITY OF PATENTS	Patent Rules, 1:54
· · · ·	Purpose, 1:2
Generally, 11:1 et seq. Conditions, 11:19	Statute of Monopolies, 1:58
Double patenting, 11:13 to 11:18	PERSON SKILLED IN THE ART
Evidence, relevant, 11:19 to 11:12	Construction of a patent
commercial success, 11:12	consideration of the understanding of a
proof of patents, 11:10	person skilled in the art, 8:1, 8:2,
record file, 11:11	8:13 to 8:18
Grant, 11:1	appropriate approach, 8:16
Grant subject to adjudication, 11:4	meaning of technical terms, 8:26
Grounds of invalidity, 11:8	purposive construction, 8:24
Invalid claims, 11:7	purposive construction, essential and
Maintenance feeds, 11:20	non-essential elements, 8:31 to
Marking of patented articles, 11:21 to	8:35, 13:10
11:24	Double patenting, 11:14
benefit, 11:22	Novelty
Canadian law, 11:21	construction of a written description,
false representations, 11:24	5:34
offences for false marking, 11:23	disclosure as understood by a person skilled in the art, 5:18
Nature of a challenge, 11:6	· ·
Nature of the grant, 11:2	enablement, 5:21, 5:44
Presumption of validity, 11:5	interpretation of a photograph or drawing, 5:37
Prior grant, 11:13 to 11:18	Obvious to a person skilled in the art
Term of the grant, 11:3	disclosure as understood by a person
PATENTS	skilled in the art, 4:21
Generally, 1:1 et seq.	information outside the field of the
Certificate of Supplementary Protection,	person skilled in the art, 4:26
1:55	test for obviousness, Current Act, 4:9 ,
English law, 1:6 to 1:12	4:10
book of bounty, 1:9	test for obviousness, Old Act, 4:7, 4:8
British patents Acts, 1:12	The person skilled in the art
law courts, 1:7	a notional person, 4:34
monopolies, 1:6	expert evidence as to the qualities and
patents, 1:6	capabilities of the person skilled in
Governed, 1:5	the art, 4:35
Jurisdiction, limited by, 1:4	qualities and capabilities of the person
Monopoly, patent, 1:3	skilled in the art, 4:35

PERSON SKILLED IN THE ART	REISSUE—Cont'd
—Cont'd	Same invention, 12:12
The specification, 7:1 et seq.	Statutory provisions, 12:4
patent specification addressed to	Valid patent, 12:9
persons skilled in the art, 7:5, 7:6, 7:9, 7:11 to 7:16, 7:18, 7:37, 7:39	REMEDIES
to 7:44	Generally, 14:1 et seq.
Utility	Account of profits, 14:47 to 14:59
construction of a promise of utility,	apportionment, 14:56
6:10	condonation, 14:59
sound prediction of utility, 6:15	expenses, 14:55
utility as specified when put into	indirect profits, 14:57
practice by a competent person,	interest, 14:58
6:9	measure of profits, 14:49
PRIVILEGE	differential cost approach, 14:51
Patent Agent Privilege, 9:8	differential profits approach, 14:52
Privilege in Dealing with College of	full cost approach, 14:50
Patent Agents and Trademark	multiple plaintiffs, 14:48
Agents, 16:51	proof of the expenses, 14:54
Privilege in Threats Action, 15:32	Appeals, 14:75
RE-EXAMINATION	Claims of particular parties, 14:7 to 14:9
Generally, 12:32 to 12:39	licensee, 14:8
Advantages, 12:39	· ·
Disadvantages, 12:39	parent for, 14:9
Question of patentability, 12:35	patentee, 14:7
Re-examination proceeding, 12:36	Compensation for damages, 14:46
Request, 12:33	Compensatory remedies, 14:3
Request, 12.33	Costs, 14:6
REISSUE	Currency conversion, 14:64
Generally, 12:1 to 12:17	Damages, 14:17 to 14:45
Accident, 12:11	absence of licences, 14:27
Application for reissue, 12:14	alternatives, 14:43
Deemed, 12:7	damages from use, 14:28
Defective, 12:8	effect of licences, 14:26
Effect of reissue, 12:15	infringer's profits, 14:19
Error, 12:10	loss due to price reduction, 14:37 to
History	14:39
Canada, 12:3	market disruption, 14:38
U.K., 12:1	post infringement losses, 14:39
U.S., 12:2	loss of profit, 14:29 to 14:36
Inadvertence, 12:11	lost sales, 14:29 to 14:36
Inoperative, 12:8	measure of damages, 14:18
Invalid patent, 12:9	mitigation, 14:42
Jurisdiction of commission, 12:6	plaintiff's loss, 14:19
Litigation involving reissued patent	reasonable royalty, 14:41
infringement of reissued patent, 12:16	recovery of plaintiff's damages, 14:44
validity of reissue, 12:17	relevance of a non-infringing alterna-
Mistake, 12:11	tive, 14:20 to 14:25
No new matter, 12:13	lost profits on lost sales, 14:21
Purpose and nature, 12:5	Apotex v. Merck, 14:23

REMEDIES—Cont'd	SPECIFICATION—Cont'd
Damages, 14:17 to 14:45—Cont'd	Construction of, see SPECIFICATION,
relevance of a non-infringing alterna-	CONSTRUCTION OF
tive, 14:20 to 14:25 —Cont'd	Description of invention, 7:9 to 7:25
lost profits on lost sales, 14:21	clarity, 7:18
—Cont'd	ambiguity, 7:19
pre-2015 Canadian jurisprudence,	definition of materials, 7:21
14:22	errors and inaccuracies, 7:20
reasonable royalty, 14:25	proportions of ingredients, 7:22
sale of non-infringing alternative, 14:24	failure to meet disclosure requirements. 7:25
sales patentee, 14:40	good faith, 7:23
Declaration, 14:4 , 14:68	misleading matter, 7:24
Destruction on oath, 14:67	nature of the invention, 7:10
Effect of income tax, 14:65	necessity for experiments, 7:16
Election of Damages or Account of	operation and use, 7:11
Profits, 14:10 to 14:16	reference to previous documents, 7:17
choosing the remedy, 14:15	disclosure, 7:11
damages and account of profits	standards for disclosure, 7:12 to 7:15
compared, 14:11	contemplated by the inventor, 7:13
causation, 14:12	general points, 7:12
damages, 14:13	Description requirements in specific situa
discretion of court, 14:14	tions, 7:26 to 7:34
Exemplary damages, 14:60	biological material, 7:32
Injunction, 14:66	description of known matter, 7:26 distinction between old and new matter
Interest, 14:61	7:33
post-judgment interest, 14:63	matter necessarily implied, 7:27
prejudgment interest, 14:62	principle, 7:34
preventive remedies, 14:2	selection patents, 7:31
Procedural considerations, 14:69 to 14:75	size or shape, 7:28
asserting a claim as to other types of	sound prediction of utility, 7:30
alleged infringement, 14:72	utility, 7:29
compensation phase, 14:71	Drawings, 7:35
effect of judgment in a subsequent case	Historical, 7:2, 7:3
revoking the patent, 14:73	development in the U.K., 7:2
liability judgment, 14:70	evolution of Canadian laws, 7:3
Punitive damages, 14:60	Person skilled in the art, 7:5
Punitive remedies, 14:5	Relevant date, 7:7
SPECIFICATION	Statutory provisions, 7:4
Generally, 7:1 et seq.	SPECIFICATION, CONSTRUCTION
Claims, 7:36 to 7:44	OF
broader than the invention, 7:40	Generally, 8:38 to 8:47
general principle, 7:39	Alternatives, 8:41
clarity of language, 7:37	Dependence claims, 8:43, 8:44
definition of the ambit of the monopoly,	antecedent claims, 8:43
7:38	element, included or additional, 8:44
nature and function of the claims, 7:36	Inventions, single or multiple, 8:40
Common general knowledge in the art,	New result or method, 8:39
7:6	New technology, 8:47

SPECIFICATION, CONSTRUCTION	SUBJECT-MATTER OF PATENTS
OF—Cont'd	—Cont'd
Numerical limitations, 8:46	Principles and theorems, 3:15, 3:16
Promise of patent — old law, 8:38	knowledge of scientific principle, 3:16
Reference numbers, 8:42	patentability, 3:15
Reference to another claim, 8:45	Process, 3:23 to 3:35
SUBJECT-MATTER OF PATENTS	addition, 3:25
Generally, 3:1 et seq.	analogous purposes, 3:27
Biotechnology, 3:40 to 3:45	biological, 3:28
animals, 3:44	chemical, 3:28
higher life forms, 3:42	general statement, 3:23
biochemical inventions, 3:40	medical treatment of animals, 3:33
biological inventions, 3:40	mental steps, 3:29
lower life forms, 3:41	methods of medical treatment, 3:31
plants, 3:45	methods of surgical treatment, 3:31
Business methods, 3:48	new result, 3:24
	non-medical treatment, 3:32
Business plans, 3:48	old result, 3:24
Business systems, 3:48	omission, 3:25
Combinations, 3:17 to 3:22	professional skills, 3:30
aggregation, 3:19	variation, 3:25
arrangement of parts, 3:22	Products and substances, 3:36 to 3:39
common result essential, 3:18	food, 3:38
novelty of elements, 3:20	medicine, 3:38
omission and addition, 3:21	non-obviousness, 3:37
Computer programs, 3:46	novelty, 3:37
Copyright, 3:53	signals, 3:39
Data processing systems, 3:46	utility, 3:37
Definitions, 3:9 to 3:14	Selection, 3:49
art, 3:10	Statutory provisions, 3:3
composition of matter, 3:14	Trade-marks, 3:55
machine, 3:12	Unpatentable matter, 3:51
manufacture, 3:13	Offpatentable matter, 3:31
process, 3:11	THREATS OF PATENT
Development of requirements, 3:5 to 3:8	INFTRINGEMENT
Canadian requirements, 3:8	Actions for Threats of Patent Infringe-
U.K. requirements, 3:6	ment, 15:1 et seq.
U.S. requirements, 3:7	Civil Code of Quebec, 15:15
Improvements, 3:50	Common Law Action for Trade Libel
Industrial designs, 3:52	or Injurious Falsehood, 15:9 to
Integrated circuit topographies, 3:54	15:14
Inventions	Competition Act, ss. 52 and 36, 15:31
dangerous, 3:57	Consumer Protection Legislation,
ethically questionable, 3:57	15:32
immoral objects, 3:57	Patent Act, ss. 76.2 and 76.3, 15:33
Mathematical formulas, other, 3:47	Trademarks Act, s. 7(a), 15:16 to 15:30
Patentability of claimed subject-matter,	TRADEMARK AGENT
3:4	College of Patent Agents and Trademark
Patentable subject-matter, 3:2	Agents, 16:1 et seq.

INDEX

UTILITY

Generally, **6:1 et seq.**As described and claimed, **6:3**inutility, **6:3**Assessed at filing date, **6:4**As specified, **6:9**Claim inutility, **6:16**broad class, **6:18**not useful products or processes, **6:17**omits an essential element, **6:19**Dangerous result or disadvantages, **6:7**Evidence as to utility, **6:22 to 6:24**commercial success, **6:24**infringement, **6:23**Filing date, **6:13**demonstrated utility, **6:14**

UTILITY—Cont'd

Filing date, 6:13—Cont'd sound prediction of utility, 6:15
Historical, 6:2
Immoral objects, 6:8
Improvement patents, 6:20
invalidity, 6:13
In part, 6:12
Promised results, 6:10
Quantum, 6:6
Selection patents, 6:21
Statements of advantages, 6:11

VALIDITY OF PATENTS

See PATENT GRANT AND VALIDITY OF PATENTS